Excellence in Physicians/Healthcare Provider Support Programmes

Summary of work

Thromboembolic conditions, like Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) cost the NHS hundreds of millions of pounds a year and lead to tens of thousands of hospital admissions. Traditional agents have challenges; constant INR monitoring, often out of therapeutic range and can interfere with food and drink. With the introduction of Novel Oral Anticoagulants (NOACs), it’s now much easier to treat these common and costly conditions to reduce days in hospital and ensure patients are adequately protected. Despite updates to NICE guidance advocating patient access to the NOACs, uptake has been slow.

Improving Practice in Anticoagulation Care is the foundation for Bayer’s medical education offering. It is made up of three core educational initiatives, INNOVATE, X-IMPACT and Mediconf all of which have significantly impacted the management of AF, DVT and PE, while enhancing patient outcomes.

As Bayer is a leader in this field, it was imperative that it communicates the priority updates and aim to increase the confidence in the use of NOACs among healthcare providers.

Improving Practice in Anticoagulation Care has reached over 2,000 healthcare providers and generated a proven shift in behaviour which has changed current practice, challenging and improving existing standards of care.

Judges' comments

The scale and sheer comprehensiveness of Bayer’s programme ensured that it really stood out, thanks to their willingness to take on a vast task.